Tailoring Treatment for Patients With EGFR-Positive NSCLC
Key Points
-
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) have three first-line treatment options.
-
Osimertinib monotherapy is the standard of care, but combination therapies have demonstrated promising findings.
-
Community oncologists are advised to consider sequencing and the importance of individualized treatment plans.
Patients with EGFR-mutated NSCLC have three treatment options that can be used in the front line.
While osimertinib monotherapy is a standard first-line treatment, data have revealed positive findings with the combination of osimertinib plus chemotherapy and amivantamab plus lazertinib.
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Coral Olazagasti, MD, of the University of Miami Health System, provided perspective on how to guide community oncologists on treatment sequencing.
Dr. Olazagasti told colleague Chinmay Jani, MD, of the University of Miami Health System, that treating patients with EGFR-positive NSCLC is not a one-size-fits-all approach. She recommended that community oncologists have conversations with patients and work together to decide on a treatment strategy based on the patient’s lifestyle and priorities.
“It’s not necessarily to only choose the first line and think about what you’re going to do in the frontline setting, but to think about the [treatment] journey,” Dr. Olazagasti said.
Shared decision-making should also be used when reviewing treatment toxicities. Although the survival data have been positive, adverse events (AEs) can be a challenge, particularly with the amivantamab and lazertinib combination. Dr. Olazagasti advocated for tailoring therapy to the individual patient after considering AEs.